The CRISPR Patent Battle: Implications for Downstream Innovation in Gene Editing
Four expert panelists will discuss the CRISPR technology and key issues in the recent patent litigation between two universities that developed the technology via federal research grant funding. In particular, they will offer their perspectives on how the recent ruling may affect the short-term strategy of companies seeking to innovate using the CRISPR platform, and the longer-term implications of the respective universities' CRISPR licensing strategies for downstream innovation using the CRISPR platform.
Speakers:Professor Lisa Larrimore Ouellette, Stanford Law SchoolProfessor Jacob Sherkow, New York Law SchoolBruce Wexler, Partner, Chair of the Life Sciences Industry Practice Group, Paul HastingsAbram Goldfinger, Executive Director of the Office of Industrial Liaison at New York University.
Event Date & Time:Tuesday March 21, 20176:00 - 8:30pm
Event Location:NYC LawLipton Hall, D'Agostino Hall110 West 3rd Street,New York, NY
Event Contact:Annemarie Hassettannemarie.firstname.lastname@example.org